Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) represent a challenging subset of non-small cell lung cancer (NSCLC).
• Patients with EGFRexon20ins NSCLC historically face poor prognoses due to limited effective therapeutic options.

Purpose of the Study:

• To report the discovery and early clinical development of sunvozertinib, a novel EGFR tyrosine kinase inhibitor.
• To evaluate the safety, tolerability, and preliminary efficacy of sunvozertinib in patients with EGFRexon20ins NSCLC.

Main Methods:

• Preclinical evaluation in cell lines and xenograft models to assess antitumor activity.
• Phase I clinical studies to determine sunvozertinib's safety, tolerability, and efficacy at various doses.

Main Results:

• Sunvozertinib exhibited potent antitumor activity in preclinical models.
• The drug was tolerated up to 400 mg daily in Phase I studies, with common adverse events including diarrhea and rash.
• Antitumor efficacy was observed in EGFRexon20ins NSCLC patients at doses of 100 mg and higher, including those with prior treatments or brain metastases.

Conclusions:

• Sunvozertinib is a potential treatment option for the unmet medical need in EGFRexon20ins NSCLC.
• Early clinical data suggest sunvozertinib has a manageable safety profile and demonstrates promising antitumor activity.